NASDAQ:CLDXCelldex Therapeutics Stock Price, Forecast & News

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLDX stock has increased by 406.9% and is now trading at $10.29.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Celldex Therapeutics.

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Celldex Therapeutics.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.02. The biopharmaceutical company earned $2.73 million during the quarter, compared to analyst estimates of $1.28 million. Celldex Therapeutics had a negative net margin of 948.81% and a negative return on equity of 47.60%.
View Celldex Therapeutics' earnings history.

Celldex Therapeutics's stock reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

2 brokerages have issued 1 year price objectives for Celldex Therapeutics' shares. Their forecasts range from $16.00 to $18.00. On average, they expect Celldex Therapeutics' share price to reach $17.00 in the next year. This suggests a possible upside of 65.2% from the stock's current price.
View analysts' price targets for Celldex Therapeutics.

News articles about CLDX stock have been trending negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Celldex Therapeutics.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Precigen (PGEN), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), bluebird bio (BLUE) and Exelixis (EXEL).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (1.63%), Creative Planning (0.16%) and Raymond James Financial Services Advisors Inc. (0.07%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics.

CLDX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Celldex Therapeutics.

CLDX stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLDX stock can currently be purchased for approximately $10.29.

Celldex Therapeutics has a market capitalization of $232.14 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

The official website for Celldex Therapeutics is www.celldex.com.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]